March 9, 2020 / 8:27 PM / in 21 days

BRIEF-Deciphera Pharmaceuticals Announces Fourth Q4 Loss Per Share $1.31

March 9 (Reuters) - Deciphera Pharmaceuticals Inc:

* DECIPHERA PHARMACEUTICALS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

* Q4 LOSS PER SHARE $1.31

* Q4 EARNINGS PER SHARE ESTIMATE $-1.18 — REFINITIV IBES DATA

* DECIPHERA PHARMACEUTICALS - INTRIGUE PIVOTAL PHASE 3 STUDY OF RIPRETINIB IN SECOND-LINE GIST EXPECTED TO COMPLETE ENROLLMENT IN SECOND HALF OF 2020

* ENDED 2019 WITH CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $579.6 MILLION

* DECIPHERA PHARMACEUTICALS - NDA FOR RIPRETINIB FOR TREATMENT OF ADVANCED GIST ACCEPTED FOR PRIORITY REVIEW BY U.S. FDA WITH PDUFA DATE OF AUGUST 13 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below